Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zelira TherapeuticsASX:ZLD Days Sales Outstanding is 0.00 as of Jun. 2025. The stock has 7 warning signs investors should review. Among 841 Biotechnology companies, Zelira Therapeutics ranks worse than 99.64% on this metric.
The historical rank and industry rank for Zelira Therapeutics's Days Sales Outstanding or its related term are showing as below:
ASX:ZLD'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 7.68 Med: 35.4 Max: 26280
Current: 26280
During the past 13 years, Zelira Therapeutics's highest Days Sales Outstanding was 26280.00. The lowest was 7.68. And the median was 35.40.
ASX:ZLD's Days Sales Outstanding is ranked worse than 99.64% of 841
companies
in the Biotechnology industry
Industry Median: 68.98
vs ASX:ZLD: 26280.00
Zelira Therapeutics's Days Sales Outstanding
declined
from Jun. 2024 (1,580.91) to Jun. 2025 (0.00).
Warning Sign:
If a company's sales outstanding increases, it means it has difficulty collecting payments from its customers.
Zelira Therapeutics (ASX:ZLD) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Zelira Therapeutics Days Sales Outstanding Related Terms
Zelira Therapeutics Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Zelira Therapeutics's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:ZLD vs CLDI, CRIS, ARTL: Days Sales Outstanding Comparison
For the Biotechnology subindustry, Zelira Therapeutics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zelira Therapeutics Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zelira Therapeutics's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Zelira Therapeutics's Days Sales Outstanding falls into.
Zelira Therapeutics Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zelira Therapeutics (ASX:ZLD) has a Days Sales Outstanding of 0.00 as of Jun. 2025. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Zelira Therapeutics and its competitors. Over the past decade, Zelira Therapeutics' Days Sales Outstanding has ranged from 7.68 to 26,280.00. According to the industry distribution chart, Zelira Therapeutics ranks #838 out of 841 companies in the Biotechnology industry, placing it in the top 99.6%.
Is Zelira Therapeutics' Days Sales Outstanding too high?
Zelira Therapeutics' current Days Sales Outstanding is 0.00. Over the past 10 years, this metric has ranged from a low of 7.68 to a high of 26,280.00. Based on the distribution chart, Zelira Therapeutics ranks #838 out of 841 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Zelira Therapeutics' Days Sales Outstanding compare to CLDI and CRIS?
According to the Biotechnology industry distribution chart, Zelira Therapeutics ranks #838 out of 841 companies for Days Sales Outstanding. This places Zelira Therapeutics in the lower half of its industry. The industry median Days Sales Outstanding is 68.98. Historically, Zelira Therapeutics' own Days Sales Outstanding has ranged from 7.68 to 26,280.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 68.98, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Zelira Therapeutics and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 68.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zelira Therapeutics's current Days Sales Outstanding is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zelira Therapeutics stock overvalued right now?
Zelira Therapeutics (ASX:ZLD) has a current Days Sales Outstanding of 0.00. The stock's GF Value™ is A$0.12, compared to a current price of A$0.50 — trading 316.7% above its estimated fair value. The current Days Sales Outstanding is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Zelira Therapeutics (ASX:ZLD), the current Days Sales Outstanding is 0.00 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema, and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer. The company is organised into two operating segments based on geographic location of operations: Australia and United States of America.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ZLD has been successfully added to your 
